as an example Salicylic Acid/Sulfur Shampoo and Hydrocortisone Lotion Kit conflict

provided that Salicylic Acid/Sulfur Shampoo and Hydrocortisone Lotion Kit instructional materials
 
Photo :Salicylic Acid/Sulfur Shampoo and Hydrocortisone Lotion Kit
which is not Salicylic Acid/Sulfur Shampoo and Hydrocortisone Lotion Kit Generic Name: Salicylic Acid/Sulfur Shampoo and Hydrocortisone Lotion Kit (SAL i SIL ik AS id & SUL fur with hye droe KOR ti sone) Brand Name: Scalacort DK Overview Side Effects Interactions Reviews Q & A More Uses of Salicylic Acid/Sulfur Shampoo and Hydrocortisone Lotion Kit: It is used to treat skin irritation. It is used to treat skin rashes. It is used to treat dandruff. It is used to control seborrheic dermatitis. Slideshow FDA-Approved Weight Loss Drugs: Can They Help You? What do I need to tell my doctor BEFORE I take Salicylic Acid/Sulfur Shampoo and Hydrocortisone Lotion Kit? If you have an allergy to salicylic acid, sulfur, hydrocortisone, or any other part of salicylic acid/sulfur shampoo and hydrocortisone lotion kit. If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs. This medicine may interact with other drugs or health problems. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this medicine with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take Salicylic Acid/Sulfur Shampoo and Hydrocortisone Lotion Kit? All products: Tell all of your health care providers that you take salicylic acid/sulfur shampoo and hydrocortisone lotion kit. This includes your doctors, nurses, pharmacists, and dentists. Certain acne products that contain benzoyl peroxide or salicylic acid can rarely cause very bad and sometimes life-threatening allergic reactions or very bad irritation. Before first use, you may need to follow certain steps to make sure you do not have an allergic reaction. Use this medicine as you were told by the doctor or read the package label. Talk with the doctor. Use of other skin products while using salicylic acid/sulfur shampoo and hydrocortisone lotion kit may cause more irritation. Do not put on cuts, scrapes, or damaged skin. Talk with your doctor before you use other drugs or products on your skin. Use care when putting on a large part of the skin or where there are open wounds. Talk with the doctor. This medicine may cause harm if swallowed. If this medicine is swallowed, call a doctor or poison control center right away. Do not take salicylic acid/sulfur shampoo and hydrocortisone lotion kit for longer than you were told by your doctor. Use with care in children. Talk with the doctor. This medicine may affect growth in children and teens in some cases. They may need regular growth checks. Talk with the doctor. Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this medicine while you are pregnant. Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby. Shampoo: Do not give to children and teenagers who have or are getting better from flu signs, chickenpox, or other viral infections due to the chance of Reye's syndrome. Reye's syndrome causes very bad problems to the brain and liver. How is this medicine (Salicylic Acid/Sulfur Shampoo and Hydrocortisone Lotion Kit) best taken? Use salicylic acid/sulfur shampoo and hydrocortisone lotion kit as ordered by your doctor. Read all information given to you. Follow all instructions closely. All products: Do not take this medicine by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn). Use as you have been told, even if your signs get better. To gain the most benefit, do not miss doses. Wash your hands before and after use. Do not wash your hands after use if putting this on your hand. Avoid putting on healthy skin. Lotion: Shake well before use. Clean affected part before use. Make sure to dry well. Put a thin layer on the affected skin and rub in gently. Do not put on the face, underarms, or the groin area unless told to do so by the doctor. Do not use coverings (bandages, dressings, make-up) unless told to do so by the doctor. Shampoo: Shake well before use. Wet hair and scalp. Lather well and leave on as you have been told. Rinse and put on again. Rinse fully. What do I do if I miss a dose? Put on a missed dose as soon as you think about it. If it is close to the time for your next dose, skip the missed dose and go back to your normal time. Do not put on 2 doses or extra doses. What are some side effects that I need to call my doctor about right away? WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat. Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit. Skin changes (pimples, stretch marks, slow healing, hair growth). Very bad skin irritation. Weight gain. Change in eyesight. Very bad headache. What are some other side effects of Salicylic Acid/Sulfur Shampoo and Hydrocortisone Lotion Kit? All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away: Skin irritation. Stinging. Dry skin. Burning. These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch. Side Effects (complete list) If OVERDOSE is suspected: If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened. How do I store and/or throw out Salicylic Acid/Sulfur Shampoo and Hydrocortisone Lotion Kit? Store at room temperature. Do not freeze. Store in a dry place. Do not store in a bathroom. Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets. Check with your pharmacist about how to throw out unused drugs. Consumer Information Use and Disclaimer If your symptoms or health problems do not get better or if they become worse, call your doctor. Do not share your drugs with others and do not take anyone else's drugs. Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor. Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins. Some drugs may have another patient information leaflet. Check with your pharmacist. If you have any questions about salicylic acid/sulfur shampoo and hydrocortisone lotion kit, please talk with your doctor, nurse, pharmacist, or other health care provider. If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened. This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about salicylic acid/sulfur shampoo and hydrocortisone lotion kit. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using salicylic acid/sulfur shampoo and hydrocortisone lotion kit. Review Date: November 1, 2017 Next Side Effects Print this page Add to My Med List More about hydrocortisone/salicylic acid/sulfur topical Side Effects Drug Interactions Support Group En Español 0 Reviews Add your own review/rating Drug class: topical steroids Consumer resources Hydrocortisone, salicylic acid, and sulfur topical Other brands: Coraz , Scalacort DK Related treatment guides Seborrheic Dermatitis} Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Hydrocortisone / salicylic acid / sulfur topical Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! Drug Class Topical steroids Related Drugs Seborrheic Dermatitis prednisone , hydrocortisone topical , ketoconazole topical , dexamethasone , Decadron , Deltasone , ciclopirox topical , fluocinolone topical , Westcort , Loprox , Locoid , Synalar , Nizoral Topical , Sterapred , Ciclodan , Hytone , Selsun Blue , Dexasone , selenium sulfide topical , Cortaid , More... Related: Seborrheic Dermatitis} } at risk of


winding up Salicylic Acid/Sulfur Shampoo and Hydrocortisone Lotion Kit aggravating

often Carbocaine HCl traumatic

taken aback Carbocaine HCl beginners
 
Photo :Carbocaine HCl
pics Carbocaine HCl Generic Name: mepivacaine (me PIV a kane) Brand Name: Carbocaine HCl, Polocaine, Polocaine-MPF, Scandonest Overview Side Effects Dosage Professional Interactions More Breastfeeding Warnings User Reviews Support Group Q & A Pricing & Coupons What is Carbocaine HCl (mepivacaine)? Mepivacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to your brain. Mepivacaine is used as a local (in only one area) anesthetic for an epidural or spinal block. It is also used as an anesthetic for dental procedures. Mepivacaine may also be used for other purposes not listed in this medication guide. Slideshow Men's Health Month And Movember: Raising The Profile Of Men's Health One Stache At A Time What is the most important information I should know about Carbocaine HCl (mepivacaine)? Spinal numbing medications can have long-lasting or permanent effects on certain body processes . Talk with your doctor about your specific risk of nerve damage from mepivacaine. What should I discuss with my health care provider before receiving Carbocaine HCl (mepivacaine)? You should not receive mepivacaine if you have ever had an allergic reaction to any type of numbing medicine. To make sure mepivacaine is safe for you, tell your doctor if you have: liver or kidney disease; low or high blood pressure; heart disease or a history of stroke; heart rhythm disorder; coronary artery disease; epilepsy or other seizure disorder; a drug allergy; or if you regularly use any medicines (especially to treat migraine headache, depression, or mental illness). FDA pregnancy category C. It is not known whether mepivacaine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medicine. It is not known whether mepivacaine passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby. How is Carbocaine HCl (mepivacaine)given? For an epidural or spinal block, mepivacaine is injected into an area of your lower back near your spine. You will receive this injection in a hospital or surgical setting. For a dental procedure, mepivacaine is injected into the gum area inside your mouth. You will receive this injection in a dentist's office or oral surgery setting. Your breathing, blood pressure, oxygen levels, and other vital signs may be watched closely while you are receiving mepivacaine. Spinal numbing medications can have long-lasting or permanent effects on certain body processes . This includes sexual function, bowel or bladder control, and movement or feeling in your legs or feet. Talk with your doctor about your specific risk of nerve damage from mepivacaine. What happens if I miss a dose? Since mepivacaine is given as needed before a surgery or other medical procedure, you are not likely to be on a dosing schedule. What happens if I overdose? Tell your caregivers right away if you think you have received too much of this medicine. Overdose symptoms may include extreme drowsiness, seizure (convulsions), shallow breathing, or slow heart rate. What should I avoid after receiving Carbocaine HCl (mepivacaine)? After your dental procedure, avoid eating, chewing gum, or drinking hot liquids until the feeling in your mouth has returned completely. Mepivacaine can cause numbness for a long period of time. Chewing while your mouth is numb could result in a bite injury to your tongue, lips, or inside of your cheek. Carbocaine HCl (mepivacaine) side effects Get emergency medical help if you have any of these signs of an allergic reaction : hives, itching, skin redness; nausea, vomiting, sweating, feeling hot; fast heartbeats; sneezing, difficult breathing; dizziness, fainting; swelling of your face, lips, tongue, or throat. Tell your caregiver right away if you have: numbness and tingling in your mouth or lips, metallic taste in your mouth; ringing in your ears, blurred vision, slurred speech, headache; confusion, depression, severe drowsiness, feeling like you might pass out; slow heart rate, weak pulse, weak or shallow breathing; fever, neck stiffness, increased sensitivity to light; tremors or muscle twitching, feeling anxious or restless; ongoing numbness, weakness, or loss of movement in your legs or feet; loss of bladder or bowel control; loss of feeling in your lower stomach, groin, or genitals; painful or difficult urination; or fast heart rate, rapid breathing, feeling hot. Common side effects may include: anxiety, feeling restless or excited; depression, dizziness; tremors; or blurred vision, ringing in your ears. This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Side Effects (complete list) What other drugs will affect Carbocaine HCl (mepivacaine)? Other drugs may interact with mepivacaine, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using. Next Side Effects Print this page Add to My Med List More about Carbocaine (mepivacaine) Side Effects Breastfeeding Dosage Information Drug Interactions Support Group Pricing & Coupons En Español 0 Reviews Add your own review/rating Generic Availability Drug class: local injectable anesthetics Consumer resources Carbocaine Carbocaine Preservative-Free Other brands: Polocaine , Polocaine-MPF , Scandonest Plain Professional resources Carbocaine (FDA) Carbocaine Injection (FDA) Other Formulations Carbocaine 2% with Neo-Cobefrin Related treatment guides Local Anesthesia Where can I get more information? Your doctor or pharmacist can provide more information about mepivacaine. Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed. Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist. Copyright 1996-2012 Cerner Multum, Inc. Version: 2.01. Date modified: December 03, 2017 Last reviewed: May 12, 2014 Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturer Pfizer Inc. Drug Class Local injectable anesthetics Related Drugs Local Anesthesia lidocaine ophthalmic , Marcaine , bupivacaine , cocaine topical , Xylocaine Jelly , tetracaine topical , Novocain , ropivacaine , Xylocaine Topical , epinephrine / lidocaine , Lidocream , AneCream , dibucaine topical , RectiCare , Naropin , Nupercainal , Pontocaine , Bactine , Sensorcaine , mepivacaine , articaine / epinephrine , More... Carbocaine Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! Help and Support Looking for answers? Ask a question or go join the Carbocaine support group to connect with others who have similar interests. getting to know


all of sudden Carbocaine HCl to explode

to explode Allegra ODT shopper

against the law Allegra ODT hiking
 
Photo :Allegra ODT
should purchase Allegra ODT Generic Name: Fexofenadine Orally Disintegrating Tablets (FEX oh FEN a deen) Brand Name: Allegra ODT Overview Side Effects Dosage Interactions Pregnancy More Breastfeeding Warnings User Reviews Support Group Q & A Pricing & Coupons Uses of Allegra ODT: It is used to ease allergy signs. It is used to treat hives. Slideshow Flonase: Avoid These Top 9 Mistakes What do I need to tell my doctor BEFORE I take Allegra ODT? If you have an allergy to fexofenadine or any other part of Allegra ODT (fexofenadine orally disintegrating tablets). If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs. This medicine may interact with other drugs or health problems. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this medicine with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take Allegra ODT? Tell all of your health care providers that you take Allegra ODT. This includes your doctors, nurses, pharmacists, and dentists. This medicine may affect certain lab tests. Tell all of your health care providers and lab workers that you take this medicine. Talk with your doctor before you drink alcohol or use other drugs and natural products that slow your actions. If you drink grapefruit juice or eat grapefruit often, talk with your doctor. If you are 65 or older, use Allegra ODT with care. You could have more side effects. Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this medicine while you are pregnant. Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby. How is this medicine (Allegra ODT) best taken? Use Allegra ODT as ordered by your doctor. Read all information given to you. Follow all instructions closely. Avoid taking this medicine with fruit juice. Do not take antacids that have magnesium or aluminum at the same time as Allegra ODT. Talk with your doctor or pharmacist. Take on an empty stomach. Take 1 hour before or 2 hours after meals. Do not take this medicine out of the blister pack until you are ready to take it. Take Allegra ODT right away after opening the blister pack. Do not store the removed drug for future use. Do not push the tablet out of the foil when opening. Use dry hands to take it from the foil. Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it. If you have phenylketonuria (PKU), talk with your doctor. Some products have phenylalanine. What do I do if I miss a dose? If you take this medicine on a regular basis, take a missed dose as soon as you think about it. If it is close to the time for your next dose, skip the missed dose and go back to your normal time. Do not take 2 doses at the same time or extra doses. Many times Allegra ODT is taken on an as needed basis. Do not take more often than told by the doctor. Dosage Information (comprehensive) What are some side effects that I need to call my doctor about right away? WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat. What are some other side effects of Allegra ODT? All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away: Headache. Throwing up. These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch. Side Effects (complete list) If OVERDOSE is suspected: If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened. How do I store and/or throw out Allegra ODT? Store at room temperature. Store in a dry place. Do not store in a bathroom. Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets. Check with your pharmacist about how to throw out unused drugs. Consumer Information Use and Disclaimer If your symptoms or health problems do not get better or if they become worse, call your doctor. Do not share your drugs with others and do not take anyone else's drugs. Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor. Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins. Some drugs may have another patient information leaflet. Check with your pharmacist. If you have any questions about this medicine, please talk with your doctor, nurse, pharmacist, or other health care provider. If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened. This information should not be used to decide whether or not to take Allegra ODT (fexofenadine orally disintegrating tablets) or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to Allegra ODT. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine. Review Date: November 1, 2017 Next Side Effects Print this page Add to My Med List More about Allegra ODT (fexofenadine) Side Effects During Pregnancy or Breastfeeding Dosage Information Drug Interactions Support Group Pricing & Coupons 1 Review Add your own review/rating Drug class: antihistamines Consumer resources Allegra ODT Children's Allegra ODT Allegra ODT (Advanced Reading) Other brands: Aller-Ease Professional resources Fexofenadine Hydrochloride (AHFS Monograph) Fexofenadine (FDA) Other Formulations Allegra ... +3 more Related treatment guides Allergic Rhinitis Urticaria Drug Status Rx OTC Availability Rx and/or OTC C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Allegra ODT Rating 1 User Review 10 /10 1 User Review 10 Rate it! Drug Class Antihistamines Related Drugs Urticaria Zyrtec , promethazine , loratadine , cetirizine , Claritin , diphenhydramine , Benadryl , fexofenadine , doxepin , levocetirizine , Allegra , Phenergan , More... Allergic Rhinitis prednisone , Zyrtec , promethazine , fluticasone nasal , loratadine , cetirizine , Flonase , triamcinolone nasal , montelukast , Claritin , Singulair , More... Related: Hives (Urticaria) respectable


snap shots Allegra ODT in vogue

for this reason DexPak 6 Day TaperPak it is important

most beautiful DexPak 6 Day TaperPak sufficiently subtle
 
Photo :DexPak 6 Day TaperPak
most pretty DexPak 6 Day TaperPak Generic Name: dexamethasone Dosage Form: tablet Overview Side Effects Dosage Professional Interactions More Pregnancy Warnings Breastfeeding Warnings User Reviews Support Group Q & A Pricing & Coupons DexPak 6 Day TaperPak Description Dexamethasone tablets USP, 1.5 mg are for oral administration. Each tablet contains 1.5 mg of dexamethasone. Inactive ingredients are microcrystalline cellulose NF, anhydrous lactose NF, FD&C Red #40 aluminum lake, croscarmellose sodium NF, and magnesium stearate NF. The molecular weight for dexamethasone is 392.47. It is designated chemically as 9-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione. The empirical formula is C22H29F05 and the structural formula is: Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water. Slideshow The Top 10 Most Expensive Disease Treatments DexPak 6 Day TaperPak - Clinical Pharmacology Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Glucocorticoids cause varied metabolic effects. In addition, they modify the body s immune responses to diverse stimuli. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have sodium-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs including dexamethasone are primarily used for their anti-inflammatory effects in disorders of many organ systems. At equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium-retaining property of hydrocortisone and closely related derivatives of hydrocortisone. Indications and Usage for DexPak 6 Day TaperPak Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Contraindications Systemic fungal infections (see WARNINGS, Fungal infections). Dexamethasone tablets are contraindicated in patients who are hypersensitive to any components of this product. Warnings General: Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy (see ADVERSE REACTIONS). Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during, and after the stressful situation. Cardiorenal: Average and large doses of corticosteroids can cause elevation of blood pressure, sodium and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients. Endocrine: Corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Adrenocortical insufficiency may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. If the patient is receiving steroids already, dosage may have to be increased. Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage. Infections: General: Patients who are on corticosteroids are more susceptible to infections than are healthy individuals. There may be decreased resistance and inability to localize infection when corticosteroids are used. Infection with any pathogen (viral, bacterial, fungal, protozoan or helminthic) in any location of the body may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents. These infections may be mild to severe. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. Corticosteroids may also mask some signs of current infection. Fungal Infections: Corticosteroids may exacerbate systemic fungal infections and therefore should not be used in the presence of such infections unless they are needed to control life-threatening drug reactions. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure (see PRECAUTIONS, Drug Interactions, Amphotericin B injection and potassium-depleting agents). Special Pathogens: Latent disease may be activated or there may be an exacerbation of intercurrent infections due to pathogens, including those caused by Amoeba, Candida, Cryptococcus, Mycobacterium, Nocardia, Pneumocystis, Toxoplasma . It is recommended that latent amebiasis or active amebiasis be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or any patient with unexplained diarrhea. Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Corticosteroids should not be used in cerebral malaria. Tuberculosis: The use of corticosteroids in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis. Vaccination: Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered. However, the response to such vaccines cannot be predicted. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison s disease. Viral Infections: Chickenpox and measles can have a more serious or even fatal course in pediatric and adult patients on corticosteroids. In pediatric and adult patients who have not had these diseases, particular care should be taken to avoid exposure. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with immune globulin (lG) may be indicated. (See the respective package inserts for VZIG and IG for complete prescribing information.) If chickenpox develops, treatment with antiviral agents should be considered. Ophthalmic: Use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. The use of oral corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes. Corticosteroids should not be used in active ocular herpes simplex. Precautions General: The lowest possible dose of corticosteroids should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual. Since complications of treatment with corticosteroids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used. Kaposi s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement. Cardiorenal: As sodium retention with resultant edema and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency. Endocrine: Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. Gastrointestinal: Steroids should be used with caution in active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and nonspecific ulcerative colitis, since they may increase the risk of a perforation. Signs of peritoneal irritation following gastrointestinal perforation in patients receiving corticosteroids may be minimal or absent. There is an enhanced effect due to decreased metabolism of corticosteroids in patients with cirrhosis. Musculoskeletal: Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of osteoporosis at any age. Special consideration should be given to patients at increased risk of osteoporosis (e.g., postmenopausal women) before initiating corticosteroid therapy. Neuropsychiatric: Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See DOSAGE AND ADMINISTRATION.) An acute myopathy has been observed with the use of high doses of corticosteroids most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevation of creatinine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years. Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids. Ophthalmic: Intraocular pressure may become elevated in some individuals. If steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored. Information for Patients: Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision. As prolonged use may cause adrenal insufficiency and make patients dependent on corticosteroids, they should advise any medical attendants that they are taking corticosteroids and they should seek medical advice at once should they develop an acute illness including fever or other signs of infection. Following prolonged therapy, withdrawal of corticosteroids may result in symptoms of the corticosteroid withdrawal syndrome including myalgia, arthralgia, and malaise. Persons who are on corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay. Drug Interactions: Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see Drug Interactions, Hepatic Enzyme lnducers, Inhibitors and Substrates). Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme lnducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS, Infections, Vaccination). Carcinogenesis, Mutagenesis, Impairment of Fertility: No adequate studies have been conducted in animals to determine whether corticosteroids have a potential for carcinogenesis or mutagenesis. Steroids may increase or decrease motility and number of spermatozoa in some patients. Pregnancy: Teratogenic Effects: Pregnancy Category C. Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of cleft palate in the offspring. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from corticosteroids, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use The efficacy and safety of corticosteroids in the pediatric population are based on the well-established course of effect of corticosteroids, which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of nephrotic syndrome (patients >2 years of age), and aggressive lymphomas and leukemias (patients >1 month of age). Other indications for pediatric use of corticosteroids, e.g., severe asthma and wheezing, are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations. The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see ADVERSE REACTIONS). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose. Geriatric Use Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. In particular, the increased risk of diabetes mellitus, fluid retention and hypertension in elderly patients treated with corticosteroids should be considered. ADVERSE REACTIONS (listed alphabetically, under each subsection) The following adverse reactions have been reported with dexamethasone or other corticosteroids: Allergic reactions: Anaphylactoid reaction, anaphylaxis, angioedema. Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see WARNINGS, Cardiorenal ), edema, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis. Dermatologic: Acne, allergic dermatitis, dry scaly skin, ecchymoses and petechiae, erythema, impaired wound healing, increased sweating, rash, striae, suppression of reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria. Endocrine: Decreased carbohydrate and glucose tolerance, development of cushingoid state, hyperglycemia, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients. Fluid and electrolyte disturbances: Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention. Gastrointestinal: Abdominal distention, elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea, pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis. Metabolic: Negative nitrogen balance due to protein catabolism. Musculoskeletal: Aseptic necrosis of femoral and humeral heads, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, steroid myopathy, tendon rupture, vertebral compression fractures. Neurological/Psychiatric: Convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo. Ophthalmic: Exophthalmos, glaucoma, increased intraocular pressure, posterior subcapsular cataracts. Other: Abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, malaise, moon face, weight gain. To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Overdosage Treatment of overdosage is by supportive and symptomatic therapy. In the case of acute overdosage, according to the patient s condition, supportive therapy may include gastric lavage or emesis. DexPak 6 Day TaperPak Dosage and Administration For oral administration: The initial dosage of dexamethasone varies from 0.75 to 9 mg a day depending on the disease being treated. It Should Be Emphasized That Dosage Requirements Are Variable And Must Be Individualized On The Basis Of The Disease Under Treatment And The Response Of The Patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage that maintains an adequate clinical response is reached. Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient s condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. In the treatment of acute exacerbations of multiple sclerosis, daily doses of 30 mg of dexamethasone for a week followed by 4 to 12 mg every other day for one month have been shown to be effective (see PRECAUTIONS, Neuropsychiatric). In pediatric patients, the initial dose of dexamethasone may vary depending on the specific disease entity being treated. The range of initial doses is 0.02 to 0.3 mg/kg/day in three or four divided doses (0.6 to 9 mg/m2bsa/day). For the purpose of comparison, the following is the equivalent milligram dosage of the various corticosteroids: Dexamethasone, 1.5 Methylprednisolone, 8 Prednisone, 10 Triamcinolone, 8 Prednisolone, 10 Betamethasone, 1.5 Hydrocortisone, 40 Paramethasone, 4 Cortisone, 50 These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered. In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested: Dexamethasone Sodium Phosphate injection, USP 4 mg per mL: First Day 1 or 2 mL, intramuscularly Dexamethasone Tablets, USP, 1.5 mg, one-half tablet: Second Day 2 tablets in two divided doses Third Day 2 tablets in two divided doses Fourth Day 1 tablet in two divided doses Fifth Day One half tablet Sixth Day One half tablet Seventh Day No treatment Eighth Day Follow-up visit This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases. In cerebral edema , Dexamethasone Sodium Phosphate injection, USP is generally administered initially in a dosage of 10 mg intravenously followed by 4 mg every six hours intramuscularly until the symptoms of cerebral edema subside. Response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days. For palliative management of patients with recurrent or inoperable brain tumors, maintenance therapy with either Dexamethasone Sodium Phosphate injection, USP or dexamethasone tablets in a dosage of 2 mg two or three times daily may be effective. Dexamethasone suppression tests: 1. Tests for Cushing s syndrome. Give 1 mg of Dexamethasone USP orally at 11:00 p.m. Blood is drawn for plasma cortisol determination at 8:00 a.m. the following morning. For greater accuracy, give 0.5 mg of Dexamethasone USP orally every 6 hours for 48 hours. Twenty-four hour urine collections are made for determination of 17-hydroxycorticosteroid excretion. 2. Test to distinguish Cushing s syndrome due to pituitary AGTH excess from Cushing s syndrome due to other causes. Give 2 mg of Dexamethasone USP orally every 6 hours for 48 hours. Twenty-four hour urine collections are made for determination of 17-hydroxycorticosteroid excretion. How is DexPak 6 Day TaperPak Supplied Dexamethasone tablets USP 1.5mg are scored, pink, pentagonal-shaped tablets debossed ECR 86 . These are available in compliance packages of 21 tablets ( DexPak 6 Day TaperPak , NDC 0095-0089-21), 35 tablets ( DexPak 10 Day TaperPak , NDC 0095-0087-35) and 51 tablets ( DexPak 13 Day TaperPak , NDC 0095-0088-51). Storage Store at controlled room temperature 20º to 25ºC (68º to 77ºF), see USP. Dispense in tight, light resistant container as defined in the USP/NF. Rx Only Keep This and All Medications Out of the Reach of Children. Manufactured for: ECR Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC Bridgewater, NJ 08807 USA Manufactured by: Mikart, Inc. Atlanta, GA 30318 Valeant Pharmaceuticals North America LLC / are trademarks of Valeant Pharmaceuticals International, Inc. or its affiliates. MI 0087/88/89 Rev. 06/2016 Code 970A00-01 Rev. 06/2016 9535500 PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 0095-0089-21 21 Tablets DexPak 6 DAY TaperPak TAPERED ORAL STEROID THERAPY Dexamethasone Tablets USP 1.5 mg Rx only See enclosed product literature for additional information. Use Only as Directed by Physician. ECR Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC Bridgewater, NJ 08807 USA / are trademarks of Valeant Pharmaceuticals International Inc. or its affiliates. Valeant Pharmaceuticals North America LLC Store at controlled room do business from home


fantastic DexPak 6 Day TaperPak provides you with

appeared like Dexchlorpheniramine irritating

extremely good Dexchlorpheniramine fashionable
 
Photo :Dexchlorpheniramine
family Dexchlorpheniramine Generic Name: Dexchlorpheniramine (deks klor fen EER a meen) Overview Side Effects Professional Interactions Pregnancy More Breastfeeding Warnings User Reviews Drug Images Support Group Q & A Uses of Dexchlorpheniramine: It is used to ease allergy signs. What do I need to tell my doctor BEFORE I take Dexchlorpheniramine? For all patients taking dexchlorpheniramine: If you have an allergy to dexchlorpheniramine or any other part of this medicine. If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs. If you have asthma. If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking dexchlorpheniramine within 14 days of those drugs can cause very bad high blood pressure. If you are breast-feeding. Do not breast-feed while you take this medicine. Children: If your child is a premature baby or is a newborn. Do not give dexchlorpheniramine to a premature baby or a newborn. This is not a list of all drugs or health problems that interact with this medicine. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take dexchlorpheniramine with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. Slideshow Flonase: Avoid These Top 9 Mistakes What are some things I need to know or do while I take Dexchlorpheniramine? Tell all of your health care providers that you take this medicine. This includes your doctors, nurses, pharmacists, and dentists. Do not take more than what your doctor told you to take. Taking more than you are told may raise your chance of very bad side effects. Do not use longer than you have been told by the doctor. Avoid driving and doing other tasks or actions that call for you to be alert until you see how dexchlorpheniramine affects you. Avoid drinking alcohol while taking this medicine. Talk with your doctor before you use other drugs and natural products that slow your actions. If you are 65 or older, use dexchlorpheniramine with care. You could have more side effects. Use with care in children. Talk with the doctor. Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this medicine while you are pregnant. How is this medicine (Dexchlorpheniramine) best taken? Use dexchlorpheniramine as ordered by your doctor. Read all information given to you. Follow all instructions closely. Take with or without food. Take with food if it causes an upset stomach. Measure liquid doses carefully. Use the measuring device that comes with this medicine. If there is none, ask the pharmacist for a device to measure dexchlorpheniramine. What do I do if I miss a dose? If you take this medicine on a regular basis, take a missed dose as soon as you think about it. If it is close to the time for your next dose, skip the missed dose and go back to your normal time. Do not take 2 doses at the same time or extra doses. Many times dexchlorpheniramine is taken on an as needed basis. Do not take more often than told by the doctor. What are some side effects that I need to call my doctor about right away? WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat. Not able to pass urine or change in how much urine is passed. Seizures. Shakiness. Very bad dizziness or passing out. Change in eyesight. Change in balance. Any unexplained bruising or bleeding. Feeling very tired or weak. Feeling confused. A burning, numbness, or tingling feeling that is not normal. Ringing in ears. What are some other side effects of Dexchlorpheniramine? All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away: Feeling sleepy. Dizziness. Loose stools (diarrhea). Hard stools (constipation). Dry mouth. Dry nose. Feeling nervous and excitable. Not hungry. Upset stomach or throwing up. Not able to sleep. Feeling tired or weak. Thickening of mucus in nose or throat. These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch. Side Effects (complete list) If OVERDOSE is suspected: If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened. How do I store and/or throw out Dexchlorpheniramine? Store at room temperature. Protect from light. Store in a dry place. Do not store in a bathroom. Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets. Check with your pharmacist about how to throw out unused drugs. Consumer Information Use and Disclaimer If your symptoms or health problems do not get better or if they become worse, call your doctor. Do not share your drugs with others and do not take anyone else's drugs. Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor. Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins. Some drugs may have another patient information leaflet. Check with your pharmacist. If you have any questions about this medicine, please talk with your doctor, nurse, pharmacist, or other health care provider. If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened. This information should not be used to decide whether or not to take dexchlorpheniramine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to dexchlorpheniramine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine. Review Date: November 1, 2017 Next Side Effects Print this page Add to My Med List More about dexchlorpheniramine Side Effects During Pregnancy or Breastfeeding Drug Images Drug Interactions Support Group 4 Reviews Add your own review/rating Drug class: antihistamines Professional resources Dexchlorpheniramine (FDA) Dexchlorpheniramine (Wolters Kluwer) Related treatment guides Allergic Reactions Allergic Rhinitis Drug Status Rx Availability Prescription only B Pregnancy Category No proven risk in humans N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Dexchlorpheniramine Rating 4 User Reviews 7.8 /10 4 User Reviews 7.8 Rate it! Drug Class Antihistamines Related Drugs Allergic Reactions prednisone , promethazine , loratadine , triamcinolone , diphenhydramine , Benadryl , EpiPen , Phenergan , epinephrine , cyproheptadine , Deltasone , chlorpheniramine , More... Allergic Rhinitis prednisone , Zyrtec , promethazine , fluticasone nasal , loratadine , cetirizine , Flonase , triamcinolone , montelukast , Claritin , Singulair , More... Dexchlorpheniramine Images Dexchlorpheniramine systemic 4 mg (Amide 014 ) View larger images at the moment


make the most Dexchlorpheniramine perhaps

advertising The Power of Community enormous

at the same time as The Power of Community trustworthy
 
Photo :The Power of Community
forte May 19, 2015 By Andrea Blanch, Ph.D. and David Shern, Ph.D. Two weeks ago, Liberia was officially declared Ebola free. Liberia was ground zero of the Ebola epidemic, with confirmed cases in all 15 counties and almost 5,000 Ebola-related deaths. Chronic poverty and years of civil war had devastated the country s health care system. At the height of the epidemic, containing the disease seemed almost impossible. But the last reported case was in March. What led to this turnaround? Several factors contributed. Donor nations and international aid groups poured expert assistance into the country. President Ellen Sirleaf-Johnson also provided important national leadership. While admitting to early mistakes - including the imposition of a tough security crackdown that fed public fears her government led a highly effective public education campaign that played a key role. But commentators have been consistent in giving another group the biggest share of the credit Liberian citizens themselves. Neighborhood groups rooted out the virus by going house by house, locating individuals who were sick. They worked to change behaviors, like washing bodies after death, long-rooted in cultural traditions. It was their action that ultimately turned the tide on the outbreak. As in Liberia, communities across the United States are mobilizing to fight another type of epidemic . We have recently summarized research showing how toxic stress and trauma are affecting the health and wellbeing of the U.S. population. These problems are reflected in declining academic performance, high levels of violence, the highest incarceration rate in the world, mental health and substance abuse problems, and many other indicators of declining human capital. This week, the Substance Abuse and Mental Health Services Administration took an important step in recognizing this epidemic and identifying potential solutions. They convened a meeting of citizen teams from six communities that are mobilizing for action. The passion, commitment and creativity these individuals bring to their task is beyond inspiring. Most are working as volunteers or are doing this work in addition to their paid employment. All understand the lesson from Liberia that turning the tide on violence and trauma will require widespread citizen involvement in concert with professional expertise. Each community has unique strengths and problems, and each has taken different initial steps. In Kansas City, police are eagerly embracing a program to address the trauma they experience in their lives and work, and the Chamber of Commerce is encouraging members to become trauma-informed. In Philadelphia, inner city residents are rebuilding community cohesion through citizen public art, and gang violence is being reduced through prevention and intervention. San Francisco is training the entire public health department (all 9,000 staff) in cultural humility and trauma-informed approaches. Walla Walla has demonstrated how using a trauma-informed approach can turn around a failing school, dramatically reducing suspensions and improving academic performance. Tarpon Springs has organized hundreds of citizens to work towards a safer and healthier community, and is helping former prisoners succeed in the community by addressing childhood trauma. In Worcester, people in recovery from mental illness, substance abuse, and trauma have led a community-wide effort to increase compassion and to celebrate differences. These efforts and others like them - need to be expanded and replicated as quickly as possible. Communities all across the country are reeling from racially charged incidents, outbreaks of violence, and mass shootings. A participant from Baltimore noted that although the city currently looks calm, some neighborhoods have been flooded with drugs and have seen a steep spike in homicides since the end of the riots. These problems are not unrelated. They reflect our failure to address social conditions that create toxic levels of stress for many of our most vulnerable citizens. David Nabarro, UN special envoy, said about Liberia: Fundamentally, this is about the extent to which societies change their behaviors, how they change them, and the speed at which they change them. In Liberia, once people understood they were faced with a devastating infectious threat, they changed quickly and dramatically. Ultimately, untold thousands of lives were saved. The threat facing us may not be as dramatic as Ebola, but it is just as deadly. If we are going to put an end to the current epidemic of toxic stress, violence and trauma, we have to change just as quickly and dramatically as Liberia did. The federal government took a welcome step in this direction this past week. Additional resources: http://www.mentalhealthamerica.net/issues/toxic-stress-behavioral-health-and-next-major-era-public-health http://www.samhsa.gov/ http://www.mentalhealthamerica.net/blog/kansas-city-gets-it-right http://www.philaceasefire.com/ http://www.leapsf.org/pdf/Trauma-Informed-Systems-Initative-2014.pdf http://communityresiliencecookbook.org/tastes-of-success/the-walla-walla-washington-story/ http://www.peace4tarpon.org/ https://www.youtube.com/watch?v=EQhqkZSvKs8&feature=youtu.be Andy Blanch, PhD, has been an advocate for the development of trauma-informed public policies and programs for the past 30 years. Dr. David Shern is the Senior Science Advisor at Mental Health America having served as its President/CEO from 2006-2014. He also has a faculty appointment in the Department of Mental Health at the Hopkins Bloomberg School of Public Health and previously was a Dean and Professor at the University of South Florida. Tags: Upstream New Public Health Mental Health America Blog a chronic


weighing machine The Power of Community frequently

reasonably priced Evolocumab try and

your corporation Evolocumab you haven't any
 
Photo :Evolocumab
enterprise [13:<30 mL/minute per 1.73 m 2 ). 1 Common Adverse Effects Nasopharyngitis, 1 2 3 upper respiratory tract infection, 1 3 influenza, 1 3 back pain, 1 2 injection site reactions (e.g., erythema, pain, bruising), 1 cough, 1 urinary tract infection, 1 sinusitis, 1 headache, 1 2 myalgia, 1 dizziness, 1 musculoskeletal pain, 1 3 hypertension, 1 diarrhea, 1 gastroenteritis. 1 3 Very low levels of LDL cholesterol (e.g.,> <25 mg/dL) occurred in clinical studies. 1 32 33 34 Although adverse consequences were not identified, long-term effects not known. 1 18 34 Interactions for Evolocumab Specific Drugs Drug Interaction Comments HMG-CoA reductase inhibitors (statins) Decreased peak plasma concentration and AUC of evolocumab by approximately 20%; however, not considered clinically important 1 No dosage adjustment required 1 Evolocumab Pharmacokinetics Absorption Bioavailability Absolute bioavailability approximately 72% after sub-Q injection. 1 Onset Following sub-Q administration, maximal suppression of free PCSK9 occurs within 4 hours. 1 Plasma Concentrations Peak plasma concentrations achieved in approximately 3 4 days following single sub-Q dose. 1 6 Following multiple dosing, accumulation ratio is approximately two- to threefold; steady-state serum trough concentrations achieved by 12 weeks. 1 Special Populations In patients with mild or moderate hepatic impairment (Child-Pugh class A or B), peak plasma concentrations and systemic exposure reduced by approximately 20 30 and 40 50%, respectively. 1 Exposure decreases with increasing body weight, but not considered clinically important. 1 Distribution Extent Crosses the placenta. 1 Not known whether distributed into milk. 1 Elimination Elimination Route Concentration-dependent. 1 At low concentrations, occurs principally through saturable binding to the PCSK9 target; at high concentrations, occurs principally through a nonsaturable proteolytic pathway. 1 10 Half-life Approximately 11 17 days. 1 Stability Storage Parenteral Solution for Injection 2 8 C. 1 Store in original carton to protect from light. 1 Do not shake, freeze, or expose to temperatures> 25 C or direct sunlight. 1 15 16 May store prefilled syringes and auto-injectors at room temperature (i.e., up to 25 C) in original carton, but must use within 30 days if stored under these conditions. 1 Discard drug if not used within 30 days. 1 Actions Fully human IgG 2 monoclonal antibody that binds to human PCSK9. 1 3 4 6 7 10 11 12 Produced in genetically engineered mammalian (Chinese hamster ovary) cells. 1 PCSK9 is a serine protease produced principally in the liver. 6 7 10 11 12 Major function of PCSK9 is to promote degradation of LDL receptors, the primary receptors responsible for clearing circulating LDL cholesterol. 1 17 Evolocumab binds specifically and with high affinity to PCSK9; inhibition of PCSK9 increases number of receptors available to clear LDL cholesterol, and consequently reduces plasma concentrations of LDL cholesterol. 1 3 6 7 10 17 19 Reductions in lipoprotein (a), apolipoprotein B, and other lipid fractions also demonstrated. 1 2 3 4 32 In patients with homozygous familial hypercholesterolemia, severity of mutation and corresponding residual LDL receptor activity affects response to evolocumab therapy. 1 3 10 Patients with 2 receptor-defective mutations (corresponding to relatively functional LDL receptor activity) appear to derive the greatest benefit, patients with one negative mutation (corresponding to very little or no LDL-receptor activity) and one defective mutation have a lesser response; those with 2 receptor-negative mutations are not expected to respond at all. 1 3 10 (See Homozygous Familial Hypercholesterolemia under Uses.) Advice to Patients Importance of reading manufacturer s patient information 13 and instructions for use 15 16 prior to starting therapy and each time the prescription is refilled. 1 Importance of discontinuing evolocumab and promptly seeking medical attention if any signs or symptoms of serious hypersensitivity (e.g., severe pruritus, rash, or redness; swollen face; difficulty breathing) occur. 1 13 (See Hypersensitivity under Cautions.) Importance of instructing patients and/or caregivers on the preparation and sub-Q administration of evolocumab, including use of the prefilled injection syringes and auto-injectors and proper aseptic technique. 1 Importance of informing patients that injection of evolocumab may take up to 15 seconds to complete. 1 Importance of patients informing their clinician if they have an allergy to latex. 1 Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses. 1 13 Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. 1 13 (See Pregnancy in Cautions.) Importance of informing patients of other important precautionary information. 1 (See Cautions.) Preparations Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations. Evolocumab Routes Dosage Forms Strengths Brand Names Manufacturer Parenteral Injection, for subcutaneous use 140 mg/mL Repatha (available as single-use prefilled syringes and auto-injectors) Amgen AHFS DI Essentials. Copyright 2017, Selected Revisions June 3, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. References 1. Amgen Inc. Repatha (evolocumab) injection prescribing information. Thousand Oaks, CA; 2015 Sept. 2. Raal FJ, Stein EA, Dufour R et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet . 2015; 385:331-40. [PubMed 25282519] 3. Raal FJ, Honarpour N, Blom DJ et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet . 2015; 385:341-50. [PubMed 25282520] 4. Sabatine MS, Giugliano RP, Wiviott SD et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med . 2015; 372:1500-9. [PubMed 25773607] 5. . Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ . 1991; 303:893-6. [PubMed 1933004] 6. Cicero AF, Colletti A, Borghi C. Profile of evolocumab and its potential in the treatment of hyperlipidemia. Drug Des Devel Ther . 2015; 9:3073-82. [PubMed 26109850] 7. Reiner Z. Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol . 2015; 12:565-75. [PubMed 26076948] 8. Ito MK, McGowan MP, Moriarty PM et al. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol . 2011; 5(3 Suppl):S38-45. 9. Food and Drug Administration. FDA Application: Search Orphan Drug Designations and Approvals. Rockville, MD. From FDA website (http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm). Accessed [2014 01 10]. 10. Page MM, Watts GF. Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. Expert Opin Drug Metab Toxicol . 2015; 11:1505-15. [PubMed 26293511] 11. Farnier M. PCSK9: From discovery to therapeutic applications. Arch Cardiovasc Dis . 2014; 107:58-66. [PubMed 24373748] 12. Gouni-Berthold I, Berthold HK. PCSK9 antibodies for the treatment of hypercholesterolemia. Nutrients . 2014; 6:5517-33. [PubMed 25470376] 13. Amgen Inc. Repatha (evolocumab) injection patient information. Thousand Oaks, CA; 2015 Aug. 14. Marais AD, Blom DJ. Recent advances in the treatment of homozygous familial hypercholesterolaemia. Curr Opin Lipidol . 2013; 24:288-94. [PubMed 23839331] 15. Amgen Inc. Repatha (evolocumab) injection single-use prefilled SureClick autoinjector instructions for use. Thousand Oaks, CA; 2015 Aug. 16. Amgen Inc. Repatha (evolocumab) injection single-use prefilled syringe instructions for use. Thousand Oaks, CA; 2015 Aug. 17. Markham A. Evolocumab: First Global Approval. Drugs . 2015; 75:1567-73. [PubMed 26323342] 18. US Food and Drug Administration. Summary Review: BLA# 125522. From FDA website. 19. . Evolocumab (Repatha)--a second PCSK9 inhibitor to lower LDL-Cholesterol. Med Lett Drugs Ther . 2015; 57:140-1. [PubMed 26445204] 20. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J . 2011; 32:1769-818. [PubMed 21712404] 22. Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. N Engl J Med . 2015; 373:1588-91. [PubMed 26444323] 23. White CM. Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab. Ann Pharmacother . 2015; 49:1327-35. [PubMed 26424774] 24. Blom DJ, Hala T, Bolognese M et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med . 2014; 370:1809-19. [PubMed 24678979] 26. Doggrell SA, Lynch KA. Is there enough evidence with evolocumab and alirocumab (antibodies to proprotein convertase substilisin-kexin type, PCSK9) on cardiovascular outcomes to use them widely? Evaluation of Sabatine MS, Giugliano RP, Wiviott SD et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-1509, and Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1488-99. Expert Opin Biol Ther . 2015; :1-5. 27. Food and Drug Administration. Natural rubber-containing medical devices; user labeling. 21 CFR Part 801. Final rule. (Docket No. 96N-0119) Fed Regist . 1997; 62:51021-30. 28. Food and Drug Administration. Amended economic impact analysis of final rule requiring use of labeling on natural rubber containing devices. 21 CFR Part 801. Final rule. (Docket No. 96N-0119) Fed Regist . 1998; 63:50660-704. 29. Food and Drug Administration. Latex-containing devices; user labeling. 21 CFR Part 801. Proposed rule. (Docket No. 96N-0119) Fed Regist . 1996; 61:32617-21. 30. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med . 2015; 372:2387-97. [PubMed 26039521] 31. Navarese EP, Kolodziejczak M, Schulze V et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med . 2015; 163:40-51. [PubMed 25915661] 32. Reviewers' comments (personal observations) on evolocumab. 33. US Food and Drug Administration. Briefing document from the endocrinologic and metabolic drugs advisory committee. June 10, 2015. From FDA website. 34. Amgen. Thousand Oaks, CA: Personal Communication. 248. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Adult Treatment Panel III Report. From AHA web site. 269. Grundy SM, Cleeman JI, Bairey Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation . 2004; 110: 227-39. 350. Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol . 2014; 63:2889-934. [PubMed 24239923] 352. Eckel RH, Jakicic JM, Ard JD et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol . 2014; 63:2960-84. [PubMed 24239922] Next Pregnancy Warnings Print this page Add to My Med List More about evolocumab Side Effects During Pregnancy Dosage Information Support Group En Español 57 Reviews Add your own review/rating Drug class: PCSK9 inhibitors Consumer resources Evolocumab ... +3 more Professional resources Evolocumab (Wolters Kluwer) Other brands: Repatha Related treatment guides High Cholesterol High Cholesterol, Familial Heterozygous High Cholesterol, Familial Homozygous ]} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Drug Class PCSK9 inhibitors Related Drugs High Cholesterol, Familial Heterozygous atorvastatin , simvastatin , Crestor , Lipitor , pravastatin , Zocor , Zetia , lovastatin , More... High Cholesterol, Familial Homozygous atorvastatin , simvastatin , Crestor , Lipitor , Zocor , rosuvastatin , Vytorin , Repatha , More... High Cholesterol atorvastatin , simvastatin , Crestor , Lipitor , Zocor , Zetia , lovastatin , niacin , More... Evolocumab Rating 57 User Reviews 6.6 /10 57 User Reviews 6.6 Rate it!} } every body


new version Evolocumab charges

standard Evoclin (Topical) typical

of 1 Evoclin (Topical) per chance
 
Photo :Evoclin (Topical)
muscle tissues Evoclin (Topical) Generic Name: clindamycin (Topical route) klin-da-MYE-sin Overview Side Effects Dosage Professional Interactions More Pregnancy Warnings Breastfeeding Warnings User Reviews Support Group Q & A Pricing & Coupons Commonly used brand name(s) In the U.S. Cleocin T Clindacin ETZ Clindacin P Clindacin Pac Clinda-Derm Clindagel ClindaMax ClindaReach Clindets Evoclin Z-Clinz Available Dosage Forms: Gel/Jelly Pad Solution Foam Lotion Therapeutic Class: Antiacne Chemical Class: Lincosamide Slideshow Newborn Baby Health: 8 Woes From Cradle Cap And Colic To Whooping Cough Uses For Evoclin Clindamycin belongs to the family of medicines called antibiotics. Topical clindamycin is used to help control acne. It may be used alone or with one or more other medicines that are used on the skin or taken by mouth for acne. Topical clindamycin may also be used for other problems as determined by your doctor. Clindamycin is available only with your doctor's prescription. Before Using Evoclin In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered: Allergies Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully. Pediatric Studies on this medicine have been done only in adult patients, and there is no specific information comparing use of this medicine in children up to 12 years of age with use in other age groups. Geriatric Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults. Although there is no specific information comparing use of this medicine in the elderly with use in other age groups, this medicine is not expected to cause different side effects or problems in older people than it does in younger adults. Pregnancy Pregnancy Category Explanation All Trimesters B Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate studies in pregnant women OR animal studies have shown an adverse effect, but adequate studies in pregnant women have failed to demonstrate a risk to the fetus. Breast Feeding There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Interactions with Medicines Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Cholera Vaccine, Live Erythromycin Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Atracurium Metocurine Tubocurarine Interactions with Food/Tobacco/Alcohol Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco. Other Medical Problems The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially: History of stomach or intestinal disease (especially colitis, including colitis caused by antibiotics, or enteritis) These conditions may increase the chance of side effects that affect the stomach and intestines Proper Use of clindamycin This section provides information on the proper use of a number of products that contain clindamycin. It may not be specific to Evoclin. Please read with care. Before applying this medicine, thoroughly wash the affected areas with warm water and soap, rinse well, and pat dry. When applying the medicine, use enough to cover the affected area lightly. You should apply the medicine to the whole area usually affected by acne, not just to the pimples themselves. This will help keep new pimples from breaking out. You should avoid washing the acne-affected areas too often. This may dry your skin and make your acne worse. Washing with a mild, bland soap 2 or 3 times a day should be enough, unless you have oily skin. If you have any questions about this, check with your doctor. Topical clindamycin will not cure your acne. However, to help keep your acne under control, keep using this medicine for the full time of treatment, even if your symptoms begin to clear up after a few days. You may have to continue using this medicine every day for months or even longer in some cases. If you stop using this medicine too soon, your symptoms may return. It is important that you do not miss any doses. For patients using the topical foam form of clindamycin: After washing or shaving, it is best to wait 30 minutes before applying this medicine. The alcohol in it may irritate freshly washed or shaved skin. This medicine contains alcohol and is flammable. Do not use near heat, near open flame, or while smoking. To apply this medicine: Do not dispense clindamycin topical foam directly onto your hands because the foam will begin to melt on contact with warm skin. Remove the clear cap. Align the black mark with the nozzle of the actuator. Hold the can upright and press firmly to dispense. Dispense amount that will cover the affected area(s) directly into the cap or onto a cool surface. The can may be placed under cold running water if the can seems warm or the foam seems runny. A small amount of topical foam should be picked up with your fingertips and massaged gently into the affected areas until the foam disappears. Unused medicine that was removed from the can should be throw away. Since this medicine contains alcohol, it will sting or burn. In addition, it has an unpleasant taste if it gets on the mouth or lips. Therefore, do not get this medicine in the eyes, nose, or mouth, or on other mucous membranes. Spread the medicine away from these areas when applying. If this medicine does get in the eyes, wash them out immediately, but carefully, with large amounts of cool tap water. If your eyes still burn or are painful, check with your doctor. It is important that you do not use this medicine more often than your doctor ordered. It may cause your skin to become too dry or irritated. For patients using the topical solution form of clindamycin: After washing or shaving, it is best to wait 30 minutes before applying this medicine. The alcohol in it may irritate freshly washed or shaved skin. This medicine contains alcohol and is flammable. Do not use near heat, near open flame, or while smoking. To apply this medicine: This medicine comes in a bottle with an applicator tip, which may be used to apply the medicine directly to the skin. Use the applicator with a dabbing motion instead of a rolling motion (not like a roll-on deodorant, for example). Tilt the bottle and press the tip firmly against your skin. If needed, you can make the medicine flow faster from the applicator tip by slightly increasing the pressure against the skin. If the medicine flows too fast, use less pressure. If the applicator tip becomes dry, turn the bottle upside down and press the tip several times to moisten it. Since this medicine contains alcohol, it will sting or burn. In addition, it has an unpleasant taste if it gets on the mouth or lips. Therefore, do not get this medicine in the eyes, nose, or mouth, or on other mucous membranes. Spread the medicine away from these areas when applying. If this medicine does get in the eyes, wash them out immediately, but carefully, with large amounts of cool tap water. If your eyes still burn or are painful, check with your doctor. It is important that you do not use this medicine more often than your doctor ordered. It may cause your skin to become too dry or irritated. For patients using the topical suspension form of clindamycin: Shake well before applying. Dosing The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so. The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine. For topical dosage form (foam): For acne: Adults and children 12 years of age and over Apply once a day to areas affected by acne. Infants and children up to 12 years of age Use and dose must be determined by your doctor. For topical dosage forms (gel, solution, and suspension): For acne: Adults and children 12 years of age and over Apply two times a day to areas affected by acne. Infants and children up to 12 years of age Use and dose must be determined by your doctor. Missed Dose If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Storage Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing. Keep out of the reach of children. Do not keep outdated medicine or medicine no longer needed. Precautions While Using Evoclin If your acne does not improve within about 6 weeks, or if it becomes worse, check with your health care professional. However, treatment of acne may take up to 8 to 12 weeks before full improvement is seen. If your doctor has ordered another medicine to be applied to the skin along with this medicine, it is best to apply them at different times. This may help keep your skin from becoming too irritated. Also, if the medicines are used at or near the same time, they may not work properly. For patients using the topical solution form of clindamycin: This medicine may cause the skin to become unusually dry, even with normal use. If this occurs, check with your doctor. In some patients, clindamycin may cause diarrhea. Severe diarrhea may be a sign of a serious side effect. Do not take any diarrhea medicine without first checking with your doctor . Diarrhea medicines may make your diarrhea worse or make it last longer. For mild diarrhea, only diarrhea medicine containing attapulgite (e.g., Kaopectate, Diasorb) may be taken. Other kinds of diarrhea medicine (e.g., Imodium A.D. or Lomotil) should not be taken. They may make your condition worse or make it last longer. If you have any questions about this or if mild diarrhea continues or gets worse, check with your health care professional. You may continue to use cosmetics (make-up) while you are using this medicine for acne. However, it is best to use only water-base cosmetics. Also, it is best not to use cosmetics too heavily or too often. They may make your acne worse. If you have any questions about this, check with your doctor. Evoclin Side Effects Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention. Check with your doctor immediately if any of the following side effects occur: Rare Abdominal or stomach cramps, pain, and bloating (severe) diarrhea (watery and severe), which may also be bloody fever increased thirst nausea or vomiting unusual tiredness or weakness weight loss (unusual) these side effects may also occur up to several weeks after you stop using this medicine Check with your doctor as soon as possible if any of the following side effects occur: Less common Skin rash, itching, redness, swelling, or other sign of irritation not present before use of this medicine Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them: More common Dryness, scaliness, or peeling of skin (for the topical solution) Less common Abdominal pain diarrhea (mild) headache irritation or oiliness of skin stinging or burning feeling of skin Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. Side Effects (complete list) The information contained in the Truven Health Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you. The use of the Truven Health products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Truven Health and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, TRUVEN HEALTH MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Truven Health does not assume any responsibility or risk for your use of the Truven Health products. Copyright 2017 Truven Health Analytics, Inc. All Rights Reserved. Next Side Effects Print this page Add to My Med List More about Evoclin (clindamycin topical) Side Effects During Pregnancy or Breastfeeding Dosage Information Drug Interactions Support Group Pricing & Coupons 0 Reviews Add your own review/rating Generic Availability Drug class: topical acne agents Consumer resources Evoclin Other brands: Clindamax , Cleocin T , Clindagel , Clindesse , ... +8 more Professional resources Evoclin (FDA) Clindamycin Phosphate topical (AHFS Monograph) Related treatment guides Acne Perioral Dermatitis} Drug Status Rx Availability Prescription only B Pregnancy Category No proven risk in humans N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Drug Class Topical acne agents Related Drugs Acne doxycycline , clindamycin topical , erythromycin topical , minocycline , tretinoin topical , tetracycline , dapsone topical , Accutane , Vibramycin , Retin-A , isotretinoin , More... Perioral Dermatitis metronidazole topical , clindamycin topical , MetroGel , benzoyl peroxide topical , Cleocin T , MetroCream , Noritate , Clindagel , Acne Treatment , MetroLotion , Oxy-10 , PanOxyl , More... Evoclin Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! Related Questions & Answers I just started to use Evoclin foam and my skin looks worse. Is this normal? Can I expect my skin to Read more questions} } most up-to-date


political views Evoclin (Topical) you might have considered trying